CERo Therapeutics Stock Spikes 42% On Clinical Trial Site Announcement For AML Treatment

(RTTNews) - CERo Therapeutics Holdings, Inc. (CERO) soared 41.97 percent to $1.12, gaining $0.33 during Thursday's trading, after announcing that the Sarah Cannon Research Institute at Colorado Blood Cancer Institute will serve as a key clinical trial site for its Phase 1 study of CER-1236, a next-generation T cell therapy targeting acute myeloid leukemia.

The stock opened at $0.88 and has traded between $0.88 and $1.42 today, surging from the previous close of $0.80. Volume exploded to over 66 million shares, vastly exceeding the average volume of 686,000.

CERO is trading well above its 52-week low of $0.5340 but remains far below its high of $171.00.

Patient enrollment is underway, with first dosing expected by June.